Abstract. Angiogenic therapy is considered to be a promising tool for treatment of ischemic diseases. Many in vivo and in vitro assays have been developed to identify potential proangiogenic drugs and to investigate their mode of action. However, until now no validated system exists that would allow quantitation of angiogenesis in vitro in only one assay. Here, a previously established all-in-one in vitro assay based on staging of the angiogenic cascade was validated by quantitation of the effects of the known proangiogenic factors VEGF-A and FGF-2. Both growth factors were applied separately or in combination to human endothelial cell cultures derived from the heart and the foreskin, and angiogenesis was quantitated over 30 days of culture. Additionally, gene expression of VEGFR-1, VEGFR-2 and FGFR-1 at 3, 10, 20 or 40 days of cultivation was quantitated by RT-qPCR. In both cultures, VEGF-A as well as FGF-2 induced a run through all defined stages of angiogenesis in vitro. Application of VEGF-A only led to formation of irregular globular endothelial structures, while FGF-2 resulted in development of regular capillary-like structures. Quantitation of the angiogenic effects of VEGF-A and transcripts of VEGFR-1 and VEGFR-2 showed that a high VEGFR-1/VEGFR-2 ratio evoked deceleration of angiogenesis.
Introduction
Angiogenesis, i.e. the sprouting of vessels from pre-existing ones, and its inhibition, antiangiogenesis, are involved in a variety of diseases. Both, the therapeutic use of antiangiogenic drugs for treatment of cancer as well as application of proangiogenic substances to improve perfusion of ischemic tissues gain in
Materials and methods

Human endothelial cells and media
Human microvascular endothelial cells derived either from the heart muscle of a 54 year old female (HCMEC), or from the neonatal foreskin (HDMEC) were purchased from Lonza Biosciences (Verviers, Belgium; original catalogue cell culture names: HMVEC-C Cardiac MV Endo Cells and HMVECdBlNeo, respectively).
A basic medium (BM) serving as negative control was constituted by using the growth medium provided by the distributors (EBM-2/EGM-2 MV, Lonza Bioscience, Verviers, Belgium) without growth factors and with only 2% of the provided serum. This medium composition turned out to retain cell survival but did not result in any angiogenic response of cells.
For positive controls the provided growth medium was used as suggested by the distributors (positive medium, PM). This medium consisted of a mixture of several growth factors including Epidermal Growth Factor (EGF), Insulin-like Growth Factor 1 (IGF-1), hydrocortisone and some less specified components such as Bovine Brain Extract and Fetal Bovine Serum in addition to VEGF-A and FGF-2. Preliminary works in our laboratory showed that this medium stimulates endothelial cells to run through all phases of the angiogenic cascade in vitro within 30-40 days.
Growth factors
The growth factors VEGF-A (human, recombinant antigen; Strathmann Biotec, Hamburg, Germany) and/or FGF-2 (human, recombinant antigen; Strathmann Biotec, Hamburg, Germany) were added to the basic medium. Concentrations of VEGF-A and FGF-2 were determined according to Cavallaro et al. [13] , who used these factors at a concentration of 10 ng/ml. In a pilot study performed in our laboratory, the effects of both growth factors were tested at concentrations of 5 ng/ml, 10 ng/ml and 20 ng/ml. Results showed that no angiogenic effect of VEGF-A or FGF-2 could be observed at a concentration of 5 ng/ml. However, when concentrations of 10 or 20 ng/ml were used, similar angiogenic effects were recorded (unpublished data). Therefore, the concentration of 10 ng/ml of each growth factor was chosen for this study.
In vitro angiogenesis assay
Endothelial cells seeded in gelatine-coated 24-well plates (Iwaki, Tokyo, Japan) at a concentration of 4.1-4.5 × 10 4 cells per well were cultivated for 30 days. Phase-contrast microscopy was carried out daily applying an inverted microscope (Axiovert 25; Zeiss, Jena, Germany). Digital pictures were taken with a video camera (Inteq 000610; Inteq, Berlin, Germany) and the image editing system Axiovision (Version 3.0; Zeiss, Jena, Germany).
Quantitation of angiogenesis was carried out by the previously established method [3, 4] . In brief, cells were incubated in the proangiogenic medium and the changes of endothelial cell morphology observed in the course of the angiogenic cascade in vitro were classified as six defined stages (Table 1) . On the first day of investigation, visual fields were chosen randomly and defined per coordinates. Thenceforward, these visual fields were photographed every second day (investigation days). The obtained cell images were assigned to the respective stage of angiogenesis. For each visual field the time-dependent course of angiogenesis was investigated by calculating the sum of assigned stages of angiogenesis in vitro during Quantitation of angiogenesis induced by VEGF-A and FGF-2 was carried out as follows: A negative control was cultivated in BM, and three experiment groups were cultivated in BM supplemented with VEGF-A, FGF-2 as well as VEGF-A and FGF-2, respectively. Cells were also incubated in PM as positive controls; their run through the stages of angiogenesis provided a standard curve, characteristic for each cell culture. The documentation of the visual fields was performed over 30 days, every second day (15 investigation days) as described above. Two visual fields were chosen from the border area and 2 visual fields from the centre of the culture well. For each visual field, the sum of assigned stages at the 15 investigation days (S) was calculated. The proangiogenic effects of VEGF-A, FGF-2 or VEGF-A and FGF-2 were determined by calculating the ratio of the arithmetic mean of the sums of the 16 visual fields of each approach (S growthfactor j ; j = 1, . . . , 16) and the arithmetic mean of the sums of the 16 visual fields derived from the cells incubated in PM (S PM j ; j = 1, . . . , 16). Analysis of variance (ANOVA) and a post-hoc Tukey-HSD test was performed on the obtained data using the STATISTICA Vers. 6.0 software (StatSoft, Tulsa, OK, USA) to determine the differences between treatments (p < 0.05).
Quantitative analysis of VEGFR-1, VEGFR-2 and FGFR-1 transcripts by RT-qPCR
Cells were harvested on the 3rd, 10th, 20th or 40th day of cultivation. Total RNA was isolated from the cells using the Invisorb Spin Cell RNA Mini Kit (Invitek, Berlin, Germany). The isolated RNA was reverse transcribed with the First Strand cDNA Synthesis Kit (K1612, Fermenta, St. Leon-Rot, Germany). Quantitative PCR was performed with the Rotor Gene 6000 (Corbett, Wasserburg, Germany) using Maxima TM SYBR Green/Fluorescein qPCR Master Mix (2X) (Fermentas, St. Leon-Rot, Germany).
All samples were run in duplicate and each run included a serial dilution of a cDNA mix of all the samples to obtain a standard curve for each gene. Gene specific primers (Table 2) were either selected from literature or designed using RTprimerDB [26] . Analysis of gene expression with quantitative PCR (qPCR) requires the knowledge of the amount of starting material in each sample. This estimation is best performed through normalisation with multiple reference genes [40] . In this survey, 10 reference genes were initially tested between the different samples as to identify the most stable reference genes (Table 2) , which could then be used for the further normalisation. Using the GeNorm software [40] , 4 reference genes were identified for the calculation of the sample specific normalisation factors (from most stable to less stable: GAPDH, UBC, TBP and HPRT). Normalized relative quantities of the mRNA coding for VEGFR-1, VEGFR-2 and FGFR-1 were calculated using REST [31] and qBase [22] with Table 2 List of primers, used for RT-qPCR. Genes of interest: FGFR1, VEGFR-1 and VEGFR-2; reference genes: Actin, beta (ACTB), beta-2-microglobulin (B2M), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hydroxymethylbilane synthase (HMBS), hypoxanthine phosphoribosyltransferase 1 (HPRT1), ribosomal protein L13 (RPL13), succinate dehydrogenase complex, subunit A (SDHA), tyrosine 3-monooxygenase/tryptophan 5-monooxygenas (YWHAZ), TATA box binding protein (TBP), ubiquitin C (UBC) the selected set of reference genes. The REST software analyses if gene-expression is significantly different between two sample groups using bootstrap randomisation [31] . The qBase software calculates normalised relative expression quantities which can then be further used for statistical analysis. The differences in the expression of the investigated genes (p < 0.05) were calculated by applying the t-test implemented in Sigmaplot (Systat, Erkrath, Germany).
Results
Morphology of endothelial structures in course of angiogenesis in vitro induced by VEGF-A and FGF-2
Cells incubated in BM showed a polygonal shape (stage 1) during the whole investigation period and served as negative controls. Cells incubated in PM were confirmed to serve as positive controls as they ran chronologically through the defined stages of angiogenesis in vitro during the investigation period of 30 days. In HDMEC as well as in HCMEC effects on morphology were similar for each medium. The only difference consisted in the characteristic and in principle lower cell density of HCMEC displayed by an always discontinuous cell layer (Figs 1 and 2) .
In all cultures, more than 50% of cells showed an elongated shape within 2-4 days (stage 2; Figs 1a,  d, g and 2a, d, g ). The following characteristic morphological changes of endothelial cells performing angiogenesis in vitro were observable in all specimens at the latest after 18 days, as stated in Table 1 
Quantitation of angiogenesis in vitro induced by VEGF-A and FGF-2
The cells incubated in BM remained in stage 1 of angiogenesis in vitro throughout the study. As a consequence these served as negative control, and were omitted from the statistical analysis.
Incubation of endothelial cells in PM led to a chronological run through all stages of angiogenesis. Therefore, endothelial cells incubated in PM served as positive control and the sum of assigned stages of angiogenesis in these cultures (S (Table 3) .
Comparing the sum of assigned stages for HCMEC and HDMEC cultured in the same medium, S was equal for HCMEC and HDMEC (Table 3) . Table 3 Sums of assigned stages of angiogenesis (S) evaluated in in vitro cultures of human heart (HCMEC) and dermal microvascular endothelial cells (HDMEC) in positive medium (PM) or in a basic medium supplemented with either VEGF-A or FGF-2, or both VEGF-A and FGF-2. Four visual fields per well were evaluated and mean values per well together with a mean for each group are presented. Mean values marked with different letters differ significantly (p < 0.05): a, b -differences between cell types cultured in the same medium. A, B, C -differences between medium within one cell type. n -number of visual fields 
Quantitation of gene expression of VEGF-A and FGF-2 receptors VEGFR-1, VEGFR-2 and FGFR-1
For evaluating the effects of VEGF-A and FGF-2 on angiogenesis in vitro, the gene expression of their endothelial specific receptors VEGFR-1, VEGFR-2 and FGFR-1 was measured at different time points, i.e. day 3, 10, 20 and 40 of cultivation. Regarding the course of expression of each receptor, in both cultures the concentration of VEGFR-1 was higher at day 3 than at day 40. VEGFR-1 showed an intermittent increase from day 3 to day 10 in HDMEC (Fig. 5) . The ratio of VEGFR-2 was approximately constant at the different times of investigation in both cultures with minor variability at day 10 and 20 ( Fig. 5) . The concentration of FGFR-1 increased from day 3 to day 40; in HCMEC the highest value was measured at day 20, whereas in HDMEC the concentration of FGFR-1 increased continuously over the study (Fig. 5) .
Considering the mean amount at all points of investigation ( Fig. 6 ), VEGFR-1 was significantly down-regulated in HCMEC compared to HDMEC (p < 0.001), whereas the concentration of VEGFR-2 or FGFR-1 showed no differences between HCMEC and HDMEC. Comparison of the ratio of the both VEGF-receptors within each culture demonstrated that VEGFR-1 was significantly higher than VEGFR-2 in HDMEC (p < 0.001). In contrast, VEGFR-1 was significantly lower than VEGFR-2 in HCMEC (p < 0.05).
Discussion
Until now, no validated in vitro cell culture system exists in the field of angiogenesis research for preclinical investigation and quantitation of the effects of potentially pro-or antiangiogenic factors. Moreover, all available in vitro assays are restricted in mutual comparability as they focus on only one phase of the angiogenic cascade, i.e. migration, proliferation or tube formation [2, 5] . Therefore, we established an all-in-one assay for quantitation of angiogenesis and antiangiogenesis in vitro that is based on staging of the angiogenic cascade [3, 4] . In the present study this assay was used to investigate and quantitate . In HDMEC VEGFR-1 was expressed significantly higher than VEGFR-2 as well as VEGFR-1 and VEGFR-2 in HCMEC (p < 0.001). In HCMEC VEGFR-2 was expressed significantly higher than VEGFR-1 (p < 0.05). FGFR-1 was expressed not significantly higher in HCMEC than in HDMEC.
angiogenesis in vitro induced by VEGF-A and FGF-2 in two different human microvascular endothelial cell cultures, derived from the heart (HCMEC) and the skin (HDMEC). For this purpose, VEGF-A and FGF-2 were either applied separately or in combination to both cultures. Additionally, gene expression of their blood vessel endothelial specific receptors, i.e. VEGFR-1, VEGFR-2 and FGFR-1, was quantitated for interpretation and evaluation of the observed effects of the factors on angiogenesis in vitro.
Application of the growth medium provided by the distributor, which was used as positive medium (PM), as wells as VEGF-A, FGF-2 or their combination led both cultures to run through the defined stages of angiogenesis in vitro. This means, that cells of both showed chronologically morphological alterations including elongation, linear arrangement, networking and development of capillary-like structures, which were taken as the basis for the staging of the angiogenic cascade in vitro. However, one difference was found in morphology of developing capillary-like structures, which was subjected to the growth factor used. Incubation of both endothelial cell cultures in VEGF-A led to the development of irregular globular structures alternating with very thin strand-like structures in stage 5 and 6. This phenomenon could also be observed in vivo during neonatal development of coronary capillaries in mice lacking ␤3-integrin, which modulates VEGF-A induced angiogenesis during the remodelling phase leading to vessel maturation [41] . Due to the successional overshoot of VEGF-A coronary capillaries failed to mature and continued to exhibit irregular endothelial thickness [41] . Furthermore, the development of large, irregular and tortuous vessels in tumours is known to be implicated in high expression levels of VEGF-A [15, 29] . These effects can be explained by the dual role of VEGF-A, acting as an angiogenic but also as a vascular permeability factor [18, 19] .
Not least, this is the reason why application of VEGF-A alone emerged to be insufficient in angiogenesis therapy [44] . VEGF-A mediates these effects mainly by its receptor VEGFR-2 [17, 32] , which was expressed similarly in HCMEC and HDMEC. Therefore, the development of irregular structures could be observed in both endothelial cell cultures treated with VEGF-A alone. In opposite, in cultures incubated either with VEGF-A in combination with FGF-2 or only with FGF-2 regular strand-like structures with diameters up to 30 m developed in stage 5-6. FGF-2 is stated to be an equally potent stimulator of angiogenesis as VEGF-A [7] . However, the results of the present study show that there might be a difference in the quality of the angiogenic effects. A comparative study on the effect of FGF-2 on tumour growth and angiogenesis in vivo revealed that high expression levels of FGF-2 in the absence of VEGF-A led to highly vascularised tumours with regular, mature and impermeable vessels [19] . This could be explained by the fact that FGF-2 lacks an effect on vascular permeability [9, 19] .
Quantitation of angiogenesis in vitro induced by VEGF-A and FGF-2 in HCMEC and HDMEC showed differences in velocity of the course of stages of angiogenesis depending on the growth factor as well as on the endothelial cell culture used. The slowest run of angiogenesis was observed in HCMEC cultured in PM. However, this culture showed the fastest run of angiogenesis in the presence of VEGF-A alone as well as in the presence of VEGF-A in combination with FGF-2. Incubation of HDMEC with VEGF-A alone resulted in a slower run of angiogenesis in comparison to PM. In addition, the combination of both growth factors provoked a similar pace of angiogenesis as compared to incubation in PM. Summing up these findings, it is obvious that application of VEGF-A accelerated angiogenesis in HCMEC, but not in HDMEC. Considering the expression level of the receptors VEGFR-1 and VEGFR-2, HCMEC showed a significant lower expression of VEGFR-1 than HDMEC, while the concentration of VEGFR-2 was similar in both cultures. Thus, in HCMEC the expression of VEGFR-1 was significant lower than the expression of VEGFR-2. These observation allows the conclusion that low expression levels of VEGFR-1 result in an increase of angiogenic effects of VEGF-A, whereas a high VEGFR-1/VEGFR-2 ratio decelerates angiogenesis in vitro induced by VEGF-A. This phenomenon can be explained by the angiogenic signalling pathways of VEGFR-1 and VEGFR-2: It is known, that activation of VEGFR-1 inhibits the proangiogenic effects of VEGF-A via VEGFR-2 by sequestering this factor and thus making it less available to VEGFR-2 [12] . Therefore, VEGFR-1 is suggested to function primarily as a decoy receptor or as a non-signalling 'reservoir' for VEGF-A. Displacing VEGF-A from VEGFR-1 provides additional VEGF-A available to induce VEGFR-2-mediated angiogenic signalling [27] . The proangiogenic effects of VEGF-A are essentially provoked by activation of VEGFR-2, which induces the initial steps of angiogenesis, i.e. migration and proliferation of vascular endothelial cells [7, 32, 37, 38] .
Application of FGF-2 showed in both cultures a similar run of angiogenesis. This observation was as expected, because FGFR-1 was expressed equally in both endothelial cell cultures. However, in comparison to cultures incubated in PM, FGF-2 yielded acceleration of angiogenesis in HCMEC and deceleration of angiogenesis in HDMEC. This might be assigned to the distinct velocity of angiogenesis influenced by PM in the different cultures. This will be investigated in a further study on analysis of the other growth factors containing in PM, which was named by the distributor, as well as their corresponding receptors.
In conclusion, the established all-in-one angiogenesis assay was used successfully for quantitation of angiogenesis in vitro induced by VEGF-A and FGF-2, and the proangiogenic effects of these growth factors were confirmed. It was further demonstrated that application of VEGF-A alone resulted in incomplete and aberrant angiogenesis. In addition, the expression of the distinct receptors VEGFR-1 and VEGFR-2 seemed to provoke quantitative effects of VEGF-A on angiogenesis in vitro. Thus, it becomes apparent that statements on qualitative effects of VEGF-A or FGF-2 on angiogenesis in vitro are comparable in the different endothelial cultures used. However, quantitative effects are particularly affected by the corresponding receptors, and therefore, cannot be extrapolated from one to another endothelial cell culture.
